Robert Miller is a force in front of his congregation. Preaching is his life's work. His life's battle started 11 years ago when he was diagnosed with prostate cancer.
"All I heard was the word cancer and I'm thinking cancer, death, cancer, death,” Miller shares.
PSA levels, the markers for prostate cancer, are considered high at four. At diagnosis, Robert’s levels were nearly 80. His prostate was removed, but the cancer stayed behind. He soon found Doctor Michael Carducci.
When prostate cancer spreads, it first goes to the bones. Doctor Carducci is studying the drug atrasentan to keep the cancer from getting there.
"This may not necessarily kill cancer cells per se, it may slow prostate cancer down to a trickle,” says Dr. Carducci.
It does that by targeting endothelin, a protein overproduced in men with prostate cancer that has spread.
"We get to the lock before endothelin does and therefore, the cancer cells never see this growth factor, this protein that really stimulates further growth,” Dr. Carducci says.
Studies show there was a 52 percent delay in the time it took for the cancer to progress. Robert still has cancer, but it hasn't reached his bones.
There are three separate studies on atrasentan for prostate cancer currently ongoing. To find out more about any of the three studies and to see if you're a candidate, log onto www.ivanhoe.com/menshealth
If you would like a transcript and an address to write to for more information, check out the Medical Breakthroughs Web site on the Internet at www.ivanhoe.com